Transcenta Holding Limited

創勝集團醫藥有限公司

(registered by way of continuation in the Cayman Islands with limited liability)

(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT
BUSINESS UPDATE ON THE FIRST PATIENT DOSED IN CHINA STUDY OF ANTI-SCLEROSTIN MONOCLONAL ANTIBODY TST002 FOR THE TREATMENT OF OSTEOPOROSIS

This announcement is made by Transcenta Holding Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but no otherwise defined shall have the same meaning ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the "**Board**") is pleased to announce the successful dosing of first patient in China Phase I Study of TST002 for the treatment of osteoporosis.

This Phase I clinical trial is a randomized and double-blind, placebo-controlled, single-ascending-dose, multi-center study designed to evaluate the safety, tolerability, and pharmacokinetics profile of TST002 as a treatment in patients with osteoporosis.

TST002 (Blosozumab) is a humanized anti-sclerostin monoclonal antibody as a drug candidate for osteoporosis and other bone loss diseases. It has a dual effect possessing both anabolic and anti-resorptive effects, which stimulates bone formation and inhibits bone absorption, resulting in fast increase in bone mineral density and bone strength. Blocking sclerostin activity in human treated with anti-sclerostin antibody or with naturally occurring genetic deletion has been shown to be an effective approach in increasing bone mineral density (BMD) and reducing bone fracture. Currently there is no approved anti-sclerostin antibody therapy in China yet, although Romosozumab from Amgen has been approved in the United States, Europe and Japan.

The Company in-licensed Blosozumab (TST002) from Eli Lilly and Company (the "**Eli Lilly**") for development and commercialization in Greater China in 2019. Eli Lilly has completed phase II clinical studies of Blosozumab in the United States and Japan and obtained promising safety profile and efficacy data. We successfully completed technology transfer, established manufacturing process in our Hangzhou HJB facility, and completed GMP production for clinical use as well as the additional preclinical studies as required by the CDE for TST002 IND application in China. IND for TST002 China study was cleared from the NMPA on September 22, 2021 for testing TST002 directly in patients with osteopenia.

"TST002 can potentially become the second anti-sclerostin monoclonal antibody in the world." said Dr. Michael Shi, our EVP, Head of Global R&D and CMO. "We look forward to conducting in-depth study to further evaluate the safety and tolerability of TST002 and bring more efficient and diversified treatment options for Chinese patients with osteoporosis."

Currently there are over 100 million of people with various degree of osteoporosis in China and over four million of them are suffering from osteoporotic fractures. These numbers are increasing due to the influence of lifestyle, diet and aging population, which result in significant health, economic and social burdens associated with osteoporosis related fractures. There are significant unmet needs in this disease area especially in patients with severe osteoporosis despite the availability of a number of agents anti-resorptives such as bisphosphonate and anti-RANKL inhibitor and anabolic agent targeting PTH.

Cautionary statement: We cannot guarantee that we will be able to develop, or ultimately market, TST002 successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director and Chief Executive Officer

Hong Kong, April 28, 2022

As at the date of this announcement, the board of directors of the Company comprises Dr. Xueming Qian as executive Director and chief executive officer, Dr. Michael Ming Shi, Mr. Albert Da Zhu and Mr. Xiaolu Weng as executive Directors, Dr. Yining (Jonathan) Zhao as chairman and non-executive Director, and Mr. Jiasong Tang, Dr. Jun Bao and Mr. Zhihua Zhang as independent non-executive Directors.